What did @nbcsouthflorida actually say?
NBC South Florida reported that the FDA issued a warning letter to Novo Nordisk, the maker of Ozempic and Wegovy, for "failing to report potential side effects" in patients. The report specified that three deaths were involved, including one death by suicide, and that the company allegedly failed to investigate or report these events. The anchor was careful to add that "the FDA did not say the medications caused the deaths." That caveat matters enormously, and credit to the reporter for including it. The claim is essentially: Novo Nordisk violated pharmacovigilance reporting requirements, not that the drugs killed anyone. That is a meaningful distinction, and this segment mostly gets it right. The problem is the framing. Leading with "potential side effects" when describing deaths that have not been causally linked to the drug is a subtle but real distortion of what a warning letter actually is.
Does the science back this up?
The FDA warning letter itself is the primary source here, and its existence is not in dispute. Novo Nordisk received a formal warning from the FDA's Center for Drug Evaluation and Research related to adverse event reporting obligations under 21 CFR Part 314. Companies that hold approved drug applications are legally required to report serious adverse events, including deaths, within 15 days of becoming aware of them, regardless of whether causality has been established. That is the regulatory baseline. What the science cannot tell us yet is whether semaglutide has any independent association with suicidality. The European Medicines Agency launched a review in 2023 examining GLP-1 receptor agonists and signals related to self-harm and suicidal ideation, a review that was ultimately inconclusive. A 2024 analysis published in Nature Medicine by Wills et al. found no elevated suicidality signal in a large claims database comparing semaglutide users to those on other diabetes medications. So the pharmacovigilance failure is real. The implied drug-death link is not established.
What did they get wrong (or right)?
They got the core regulatory fact right. The FDA did issue a warning letter, and Novo Nordisk did face allegations of failing to report adverse events in a timely manner. That is documented and accurate. What the segment gets wrong, or at least muddies, is the implied severity hierarchy. Calling deaths "potential side effects" conflates two separate things: an unverified adverse event report and a confirmed drug reaction. A death reported to the FDA by a patient's family or physician becomes part of the adverse event database. That does not make the drug responsible. The segment also describes the company as failing to "investigate" the side effect, which is a more serious allegation than simple late reporting, and one that deserves more scrutiny than a single sentence allows. The two-week response window the FDA gave Novo Nordisk is standard for warning letters and was accurately reported. The company's statement, described as planning to "address the request fully," is boilerplate and should have been treated with more skepticism.
What should you actually know?
If you are taking semaglutide or tirzepatide, this warning letter is not a reason to stop your medication without talking to your prescriber. The FDA's pharmacovigilance system is designed to catch signals before causality is proven, which means it will sometimes flag events that turn out to have no connection to the drug. That is the system working, not failing. What this story does tell you is that Novo Nordisk allegedly sat on adverse event reports it was legally required to submit, and that is a compliance problem worth taking seriously independent of whether the drug caused any harm. The 2023-2024 regulatory scrutiny of GLP-1 drugs and mental health signals has not produced causal evidence, but the research is still active. Patients experiencing mood changes, depression, or any thoughts of self-harm while on these medications should contact their prescriber immediately. That is true for any medication, but worth repeating clearly given this news cycle.